SEEL
NASDAQSeelos Therapeutics Inc.
Seelos Therapeutics Inc. (SEEL) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for SEEL in the last 30 days. The most recent was published Dec 4, 2024.
Latest news
25 items- 13D/GAmendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)
- SECSEC Form NT 10-Q filed by Seelos Therapeutics Inc.NT 10-Q - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)
- 13D/GSEC Form SC 13G filed by Seelos Therapeutics Inc.SC 13G - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)
- SECSEC Form DEFA14A filed by Seelos Therapeutics Inc.DEFA14A - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- PRSeelos Announces Second Postponement of its Annual Meeting of StockholdersNEW YORK, Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024, from its originally scheduled date of Friday, September 27, 2024, has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Monday, November 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting, August 19, 2
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- PRSeelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter MarketNEW YORK, Oct. 15, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that on October 14, 2024, Seelos Therapeutics, Inc. (the "Company") received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Com
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSEC Form DEFA14A filed by Seelos Therapeutics Inc.DEFA14A - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- PRSeelos Announces Postponement of its Annual Meeting of StockholdersNEW YORK, Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was originally scheduled to be held on September 27, 2024, has been postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Friday, October 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting August 19, 2024, is unchanged and applies to the postponed Annual Meeting.
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- PRSeelos Therapeutics Announces 1-for-16 Reverse Stock SplitNEW YORK, Sept. 25, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-16 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Friday, September 27, 2024. The Company's common stock, par value $0.001, will begin trading on a reverse stock split-adjusted basis at the opening of the m
- SECSEC Form S-1 filed by Seelos Therapeutics Inc.S-1 - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- PRSeelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the signing of a Material Transfer Agreement (MTA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) to supply SLS-002 (intranasal racemic ketamine) for the U.S. Department of Defense's (DOD) Military and Veterans Adaptive Platform Clinical Trial ("M-PACT") to evaluate its potential for treatment of post-traumatic stress disorder (PTSD).
- SECSeelos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSEC Form EFFECT filed by Seelos Therapeutics Inc.EFFECT - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSEC Form DEF 14A filed by Seelos Therapeutics Inc.DEF 14A - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSEC Form S-3 filed by Seelos Therapeutics Inc.S-3 - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSEC Form 10-Q filed by Seelos Therapeutics Inc.10-Q - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
- SECSEC Form PRE 14A filed by Seelos Therapeutics Inc.PRE 14A - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
SEEL FAQ
7 questionsWhat does Seelos Therapeutics Inc. do?
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with...What is the latest news on SEEL?
Quantisnow has not tracked any new filings, ratings or press releases for SEEL in the last 30 days. The most recent wire item was published on December 4, 2024.Where does SEEL stock trade?
Seelos Therapeutics Inc. (SEEL) is listed on NASDAQ.What sector and industry is SEEL in?
Seelos Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SEEL?
Across the last 3 analyst actions on Seelos Therapeutics Inc., there was 1 upgrade and 0 downgrades. The most recent action was from Roth Capital: Buy with a $8.00 price target on 2021-09-27. Recent price targets range from $2.50 to $8.00.What companies are similar to SEEL?
Notable peers in the same industry include NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.). Compare SEEL side-by-side with any of them on Quantisnow.How can I track SEEL on Quantisnow?
Quantisnow aggregates Seelos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SEEL to receive live email and push alerts on every new disclosure.